Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
Over 10 years we created a diverse pipeline to bring this vision ... and ongoing support from the Cystic Fibrosis Foundation and collaboration with Therapeutics Development Network, the Company ...
As well as Orkambi, Vertex has other drugs in its pipeline that can treat a wider group of patients – it wants the NHS to fund all its approved CF drugs, and any future medications in its ...
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
Over 10 years we created a diverse pipeline to bring this vision closer to reality with seven named product candidates across three therapeutic areas utilizing three novel, clinically-validated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback